within Pharmacolibrary.Drugs.ATC.N;

model N05AA04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.3333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 0.1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0066,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0053,
    k12             = 2.7,
    k21             = 2.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AA04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Acepromazine is a phenothiazine derivative used primarily as a veterinary tranquilizer and sedative. It is commonly administered to dogs, cats, and horses for pre-anesthetic sedation, prevention of motion sickness, or for general tranquilization. Its use in humans is extremely rare today and primarily limited to veterinary medicine.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for acepromazine reported in healthy adult dogs after intravenous and intramuscular administration.</p><h4>References</h4><ol><li><p>Knych, HK, et al., &amp; Kass, PH (2018). Pharmacokinetics, pharmacodynamics, and metabolism of acepromazine following intravenous, oral, and sublingual administration to exercised Thoroughbred horses. <i>Journal of veterinary pharmacology and therapeutics</i> 41(4) 522–535. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12494&quot;>10.1111/jvp.12494</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29457257/&quot;>https://pubmed.ncbi.nlm.nih.gov/29457257</a></p></li><li><p>Marroum, PJ, et al., &amp; Curry, SH (1994). Pharmacokinetics and pharmacodynamics of acepromazine in horses. <i>American journal of veterinary research</i> 55(10) 1428–1433. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7998701/&quot;>https://pubmed.ncbi.nlm.nih.gov/7998701</a></p></li><li><p>Deshpande, D, et al., &amp; Gieseg, MA (2016). The Effect of the Canine ABCB1-1Δ Mutation on Sedation after Intravenous Administration of Acepromazine. <i>Journal of veterinary internal medicine</i> 30(2) 636–641. DOI:<a href=&quot;https://doi.org/10.1111/jvim.13827&quot;>10.1111/jvim.13827</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26822006/&quot;>https://pubmed.ncbi.nlm.nih.gov/26822006</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AA04;
